Could the recent stagnation of the stock price be due to the FDA approval of the spot competitor which was announced last week.
I know CST say this is more of a research tool but they are likely to pick up some market share however small. Is this being factored into the Cellestis sales projections and therefore affecting stock price?
- Forums
- ASX - By Stock
- pep talk needed...
Could the recent stagnation of the stock price be due to the FDA...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)